title: Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer.
abstract: BACKGROUND
  Interleukin-6 (IL-6) binds both the membrane and soluble forms of the IL-6 receptor (sIL-6R), which induces a complex with gp130, and proliferation of tumour cells. The aim of this study is to clarify the relationship between tumoral sIL-6R expression and disease progression in colorectal cancer patients.
  
  
  METHODS
  We measured tissue concentrations of sIL-6R in tumour and normal mucosa from 161 colorectal cancer patients undergoing surgery, and in supernatants from colon cancer cell lines. The expression of IL-6, IL-6R and gp130 was evaluated by immunohistochemical analysis.
  
  
  RESULTS
  Loss of tumour expression of sIL-6R as defined by sIL-6R Ca/N ratio <1.0 was significantly associated with factors reflecting disease progression, and was an independent prognostic factor not only in all the patients in this study, but also in the patients with curative intent. Colon cancer cell lines produced sIL-6R in vitro, and the production of sIL-6R in cancer cell lines was stimulated by cytokine stimulation. Immunohistochemistry revealed that loss of tumour expression of sIL-6R was significantly inversely correlated with intense IL-6 expression in the cytoplasm of cancer cells. In addition, tumoral IL-1beta expression was significantly correlated with sIL-6R expression.
  
  
  CONCLUSIONS
  Loss of tumour expression of sIL-6R is associated with colorectal cancer disease progression.
authors.affiliation: Division of Reparative Medicine, Department of Gastrointestinal and Pediatric Surgery, Institute of Life Sciences, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Okugawa
authors.forename: C
authors.initials: C
authors.lastname: Miki
authors.forename: Y
authors.initials: Y
authors.lastname: Toiyama
authors.forename: H
authors.initials: H
authors.lastname: Yasuda
authors.forename: T
authors.initials: T
authors.lastname: Yokoe
authors.forename: S
authors.initials: S
authors.lastname: Saigusa
authors.forename: J
authors.initials: J
authors.lastname: Hiro
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Inoue
authors.forename: M
authors.initials: M
authors.lastname: Kusunoki
mesh_terms: D001483:Base Sequence; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology; D017931:DNA Primers; D018450:Disease Progression; D005260:Female; D019073:HT29 Cells; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D019947:Receptors, Interleukin-6 / Q000378:metabolism*
chemical_list: D017931:DNA Primers; D019947:Receptors, Interleukin-6
references.citation: Cell Cycle. 2005 Feb;4(2):217-20
references.pmid: 15655344
references.citation: Cancer Cell. 2009 Feb 3;15(2):91-102
references.pmid: 19185844
references.citation: Blood. 1993 Aug 15;82(4):1120-6
references.pmid: 8353278
references.citation: Cancer. 1999 Jun 15;85(12):2526-31
references.pmid: 10375098
references.citation: Endocrinology. 1992 Nov;131(5):2229-34
references.pmid: 1425421
references.citation: Arch Surg. 2001 Nov;136(11):1274-9
references.pmid: 11695972
references.citation: Eur Cytokine Netw. 1999 Sep;10(3):337-44
references.pmid: 10477390
references.citation: Cancer. 2007 Nov 1;110(9):1911-28
references.pmid: 17849470
references.citation: Cancer Res. 2000 Jan 1;60(1):184-90
references.pmid: 10646872
references.citation: Cancer Res. 2005 Feb 15;65(4):1129-35
references.pmid: 15734993
references.citation: Nature. 1988 Mar 3;332(6159):83-5
references.pmid: 3258060
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):7028-34
references.pmid: 18980999
references.citation: Clin Cancer Res. 2000 Jan;6(1):172-7
references.pmid: 10656447
references.citation: FASEB J. 2001 Jan;15(1):43-58
references.pmid: 11149892
references.citation: Eur J Immunol. 1993 Feb;23(2):473-80
references.pmid: 8436181
references.citation: Immunity. 2004 Oct;21(4):491-501
references.pmid: 15485627
references.citation: J Interferon Cytokine Res. 1996 Dec;16(12):1001-6
references.pmid: 8974001
references.citation: Ann Pharmacother. 2008 Nov;42(11):1660-8
references.pmid: 18957621
references.citation: Cytokine. 2000 Sep;12(9):1331-6
references.pmid: 10975992
references.citation: Biomed Pharmacother. 2001 Sep;55(7):391-6
references.pmid: 11669502
references.citation: J Gastroenterol Hepatol. 1999 Jul;14(7):709-14
references.pmid: 10440217
references.citation: Lymphokine Cytokine Res. 1992 Jun;11(3):161-6
references.pmid: 1391235
references.citation: Cancer Cell. 2009 Feb 3;15(2):103-13
references.pmid: 19185845
references.citation: Cancer. 2003 May 15;97(10):2440-52
references.pmid: 12733143
references.citation: FEBS Lett. 1989 Jul 3;250(2):607-10
references.pmid: 2787758
references.citation: FASEB J. 1997 May;11(6):457-65
references.pmid: 9194526
references.citation: Clin Immunol. 2002 Feb;102(2):169-78
references.pmid: 11846459
references.citation: J Surg Oncol. 2003 Aug;83(4):222-6
references.pmid: 12884234
references.citation: Cancer Res. 1990 Oct 15;50(20):6683-8
references.pmid: 2208133
references.citation: Cancer Res. 1990 Dec 15;50(24):7786-8
references.pmid: 2253221
references.citation: Cancer Res. 1990 Nov 1;50(21):6959-65
references.pmid: 2208162
references.citation: Annu Rev Immunol. 1997;15:797-819
references.pmid: 9143707
references.citation: Cancer Lett. 2000 Apr 3;151(1):31-8
references.pmid: 10766420
references.citation: Scand J Immunol. 2006 May;63(5):321-9
references.pmid: 16640655
references.citation: Eur J Immunol. 1994 Aug;24(8):1945-8
references.pmid: 8056053
references.citation: Biochem J. 1994 Jun 1;300 ( Pt 2):281-90
references.pmid: 8002928
references.citation: Cancer Res. 1993 Sep 15;53(18):4175-81
references.pmid: 8364912
references.citation: Oncology. 2005;68(2-3):138-45
references.pmid: 16006751
references.citation: Ann Surg. 2010 Feb;251(2):389-90; author reply 390-1
references.pmid: 20040845